Table 1.
Studies comparing differing amounts of radiotherapy with combined modality therapy
MOPP indicates mustargen, Oncovin, procarbazine, and prednisone; and EFS, event-free survival.
Studies comparing differing amounts of radiotherapy with combined modality therapy
MOPP indicates mustargen, Oncovin, procarbazine, and prednisone; and EFS, event-free survival.
